NeoGenomics (NASDAQ:NEO - Get Free Report) is expected to issue its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to post earnings of $0.0555 per share and revenue of $206.70 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.
NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.02. The business had revenue of $201.66 million for the quarter, compared to analyst estimates of $196.93 million. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. NeoGenomics's revenue for the quarter was up 11.2% compared to the same quarter last year. During the same period last year, the firm earned $0.03 earnings per share. On average, analysts expect NeoGenomics to post ($0.09) EPS for the current fiscal year and $0.05 EPS for the next fiscal year.
NeoGenomics Trading Up 1.2%
NASDAQ NEO opened at $16.62 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.60 and a quick ratio of 3.35. NeoGenomics has a 12-month low of $7.07 and a 12-month high of $20.15. The firm has a 50-day moving average price of $17.56 and a two-hundred day moving average price of $13.56.
Analyst Ratings Changes
Several brokerages have recently commented on NEO. Wall Street Zen raised shares of NeoGenomics from a "hold" rating to a "buy" rating in a report on Saturday, June 27th. Zacks Research downgraded shares of NeoGenomics from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Piper Sandler reiterated an "overweight" rating on shares of NeoGenomics in a research note on Wednesday, October 7th. Craig Hallum reiterated a "buy" rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, July 29th. Finally, TD Cowen reissued a "buy" rating on shares of NeoGenomics in a research report on Wednesday, July 15th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $18.17.
Get Our Latest Stock Report on NeoGenomics
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc NASDAQ: NEO is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.
The company's services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.
Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
